Sign inCreate account

Report workspace tools

NCT01835236COMPLETEDanonymous

A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer

Sponsor

Source record

Swiss Cancer Institute

Phase

Source record

Phase II

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

HER2-positive Metastatic Breast Cancer

Indication / condition

AI-normalized

Metastatic Breast Cancer

Intervention

Source record

Trastuzumab, Pertuzumab, Paclitaxel, Vinorelbine, T-DM1

Source & freshness

Source record

NCT ID

NCT01835236

Original source

ClinicalTrials.gov

Source last updated

Mar 30, 2021

Ingested at

Jun 05, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT01835236

Title

A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer

Sponsor

Swiss Cancer Institute

Status

COMPLETED

Phase

Phase II

Condition raw

Metastatic Breast Cancer

Condition normalized

Metastatic Breast Cancer

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

Trastuzumab, Pertuzumab, Paclitaxel, Vinorelbine, T-DM1

Target normalized

HER2-positive Metastatic Breast Cancer

Interventions

Trastuzumab, Pertuzumab, Paclitaxel, Vinorelbine, T-DM1

Public preview

Source record

This clinical trial evaluates a novel treatment strategy for HER2-positive metastatic breast cancer, comparing a chemotherapy-free regimen of trastuzumab and pertuzumab followed by T-DM1 against a chemotherapy-inclusive regimen. The study aims to determine if the new strategy offers similar or improved efficacy and tolerability compared to standard treatments.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT01835236

Status

COMPLETED

Phase

Phase II

Sponsor

Swiss Cancer Institute

Executive brief

Investment-Ready Snapshot

This clinical trial evaluates a novel treatment strategy for HER2-positive metastatic breast cancer, comparing a chemotherapy-free regimen of trastuzumab and pertuzumab followed by T-DM1 against a chemotherapy-inclusive regimen. The study aims to determine if the new strategy offers similar or improved efficacy and tolerability compared to standard treatments.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 30, 2021
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT01835236

Indication

Metastatic Breast Cancer

Modality

monoclonal antibody

Target

HER2-positive Metastatic Breast Cancer

Intervention

Trastuzumab, Pertuzumab, Paclitaxel, Vinorelbine, T-DM1

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.